RICHMOND, Va.—Phlow Corp. recognizes the Biden Administration’s efforts to highlight the challenges facing our nation’s pharmaceutical supply chain and appreciates the extensive 100-Day Review which identifies the key features necessary to create a resilient and sustainable essential medicine supply chain. Phlow stands ready to expand its existing relationship with the U.S. Government to assist in this critically important initiative.
The Administration recognizes that creating a resilient pharmaceutical supply chain requires ongoing public-private sector engagement, upstream visibility and transparency into the source of ingredients and manufacturing sites, and identification of financial incentives beyond use of the Defense Production Act to help drive private sector willingness to develop domestic production capacity. Strategies to create a robust and resilient pharmaceutical supply chain include diversification of the supply chain by enhancing domestic manufacturing as well as providing diversity in foreign sources by leveraging partnerships with the private sector and international partners.
Everything Phlow does is designed to solve the broken essential medicine supply chain, which has led to critical drug shortages, by offering a resilient end-to-end solution that is U.S.-based, comprehensive, and fully integrated. With contract funding support from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), Phlow is currently developing a 100% U.S.- based, end-to-end, advanced manufacturing capability to produce active pharmaceutical ingredients (APIs) and affordable medicines. Phlow is building a Strategic Active Pharmaceutical Ingredient Reserve (“SAPIR”) inventory, intended to help ensure the U.S. has an uninterrupted supply of affordable essential life-saving medicine ingredients that can be rapidly converted to finished medicines. Through the use of continuous-flow and other advanced manufacturing technologies, Phlow is dedicated to reducing costs, improving quality, and sustaining our environment to ensure a healthy future for all Americans.
Phlow Corp. is a trailblazing, essential medicines impact company that is reimagining essential medicines from start to finish through the use of flow chemistry. Everything Phlow does is designed to promote access to affordable, high-quality essential medicines for all Americans. Phlow provides a solution to the broken essential medicines supply chain by offering a resilient end-to-end solution that is U.S.-based, comprehensive, and fully integrated. With the support of an industry leading team, experienced strategic partners, and established relationships at the policy, regulatory, and federal levels, Phlow will manufacture active pharmaceutical ingredients (APIs) and finished pharmaceutical products domestically for essential medicines critical to the nation’s healthcare. Through the use of continuous-flow technology and green chemistry, Phlow is able to reduce costs and waste, improve quality and yield, and offer a more environmentally friendly alternative to batch manufacturing.